Immunity to Immunotherapy in Cancer: Mechanisms and Limitations explores the intricate interplay between cancer therapy and the immune system, addressing why some patients do not respond to immunotherapy and scientific solutions in development. The book examines molecular strategies of immune evasion within the tumor microenvironment, providing insights into factors like tumor heterogeneity and immune checkpoint mechanisms that contribute to resistance. Highlighting promising approaches such as combination therapies, personalized medicine, and novel immunotherapeutic agents, the book aims to enhance patient outcomes and advance cancer immunotherapy.
Designed as a comprehensive guide for professionals and researchers, this textbook offers an overview of the latest scientific discoveries and practical applications in cancer therapy. It serves as an invaluable resource for scientists, doctors, academicians, and students, presenting a path toward more effective, non-toxic, and customized cancer treatments. This book is essential for anyone interested in the future of cancer therapy.
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
Table of Contents
Part A: Cancer Immunity1. Introduction to Immunity in Cancer
2. Role of Innate Immunity in Cancer Immunology
3. Role of Dendritic Cells in Cancer Immunology
4. Role of Natural Killer Cells in Cancer Immunology
5. Role of B-Cells in Tumor Immunity
6. Role of CD4+ T-Cells in Cancer Immunology
7. Role of Regulatory T-Cells and Th17 Cells in Tumor Microenvironment
8. Role of Monocytes, Macrophages, and Polymorphonuclear Cells in Cancer Immunology
9. Role of Cytokines in Cancer Immunology
10. Role of Chemokines and Chemokine Receptors in Cancer Immunology
11. Role of the Inflammasome in Cancer Immunology
12. Current Advanced Immunological Tools and Databases in Tumor Immunity
13. Tumor Heterogeneity and Therapeutic Resistance
Part B: Cancer Immunotherapy
14. Cancer Immunotherapy: Pros, Cons, and Beyond
15. Role of Monoclonal Antibody, Immune Checkpoint Inhibitors, and Programmed Death Ligand 1 in Cancer Immunotherapy
16. Role of Chimeric Antigen Receptor-T Cell in Cancer Immunotherapy
17. Role of Small Molecule-Based Drugs in Cancer Immunotherapy
18. Role of Adoptive Cell Therapy in Cancer Immunotherapy
19. Role of Cancer Vaccines in Cancer Immunotherapy
20. Role of Radiotherapy/Chemotherapy in Cancer Immunotherapy
Authors
Mukesh Nandave Delhi Pharmaceutical Sciences and Research University, India. Experienced Associate Professor in Pharmacology with a demonstrated history of working in national and international organisations. Strong professional skilled in Pharmaceutical Research, Molecular Biology, Inflammation, and cardiovascular and metabolic diseases. Deepa Mandlik Associate Professor at Bharati Vidyapeeth (Deemed to be University) Poona College of Pharmacy, Pune..Dr. Deepa Mandlik is an Associate Professor at Bharati Vidyapeeth (Deemed to be University) Poona College of Pharmacy, Pune. She brings extensive teaching and research experience across her career and has demonstrated outstanding academic achievement in her early training. She has published extensively in reputable national and international journals and has authored several pharmaceutical books along with multiple international book chapters. A recognized PhD guide, she mentors doctoral researchers and oversees a active cohort of postgraduate students. She is a life member of APTI and a member of CRS-Indian Chapter. Her research interests encompass nanotechnology, targeted drug delivery, quality by design, design of experiments, and optimization techniques, reflecting a strong commitment to innovation in pharmaceutical science. Dr. Mandlik is known for integrating rigorous scientific inquiry with teaching and mentorship to advance the development of the next generation of pharmaceutical researchers.
